10-Q: Cooper Companies Reports Strong Revenue Growth and Operating Income, But Faces Internal Control Weakness and Higher Tax Rate in Q2 2025

The Cooper Companies, Inc. reported increased net sales and operating income for the second quarter and first six months of fiscal 2025, driven by strong performance in both CooperVision and CooperSurgical segments, despite a material weakness in internal controls and a higher effective tax rate impacting quarterly net income.

Summary

• Net sales for the three months ended April 30, 2025, increased by 6.3% to $1,002.3 million, up from $942.6 million in the prior year period.
• Net sales for the six months ended April 30, 2025, increased by 4.9% to $1,967.0 million, up from $1,874.2 million in the prior year period.
• Gross profit for the three months increased by 7.6% to $679.1 million, with gross margin improving to 68% from 67% in the prior year.
• Operating income for the three months increased by 14.3% to $184.8 million, up from $161.7 million in the prior year.
• Net income for the three months slightly decreased by 1.3% to $87.7 million, down from $88.9 million, primarily due to a higher effective tax rate and a $15.7 million loss on disposal of a minority interest investment.
• Diluted earnings per share remained flat at $0.44 for the three months ended April 30, 2025, compared to the prior year.
• Net income for the six months increased by 12.9% to $192.0 million, up from $170.1 million, with diluted EPS increasing to $0.96 from $0.85.
• Cash provided by operating activities for the six months increased by 22.7% to $286.8 million, up from $233.7 million.
• The company repurchased 0.5 million shares of common stock for $40.6 million during the three and six months ended April 30, 2025, at a weighted average price of $75.60 per share.
• As of April 30, 2025, $215.8 million remains authorized for share repurchases under the 2012 Share Repurchase Program.
• The Board of Directors decided to end the declaration of a semi-annual dividend in December 2023.
• A material weakness in information technology (IT) general controls for the U.S. operations within the CooperSurgical segment was identified, leading to a conclusion that disclosure controls and procedures are not effective as of April 30, 2025.
• The company entered into a new $2.3 billion Revolving Credit Agreement on May 1, 2024, maturing May 1, 2029, and fully repaid previous borrowings.
• The company has $1,500.0 million outstanding under its 2021 Term Loan Facility, maturing December 17, 2026, and $1,024.5 million outstanding under the 2024 Revolving Credit Facility as of April 30, 2025.
• The effective tax rate for the three months ended April 30, 2025, was 39.3%, up from 31.6% in the prior year, primarily due to changes in valuation allowance and a decrease in excess tax benefits from share-based compensation.

Sentiment

Score: 6

Explanation: The company demonstrated strong operational performance with solid revenue growth and improved gross margins across both segments, and reduced interest expense. However, the slight dip in quarterly net income and flat EPS due to a higher tax rate and a one-time loss, coupled with the significant disclosure of a material weakness in internal controls, temper the overall positive sentiment. The cessation of dividends is also a negative for certain investors.

Positives

• Consolidated net sales increased by 6.3% for the three months and 4.9% for the six months ended April 30, 2025, demonstrating strong top-line growth.
• Gross margin improved by 1 percentage point to 68% for both the three and six months, driven by efficiency gains and a more favorable product and regional mix.
• Consolidated operating income increased significantly by 14.3% for the three months and 16.5% for the six months, indicating improved operational leverage.
• CooperVision segment showed robust performance with 5% net sales growth and 16% operating income growth for the three months, driven by Biofinity, MyDay, and MiSight products.
• CooperSurgical's Office and Surgical net sales grew by 13% for the three months, boosted by Paragard contraceptive IUDs and the acquisition of obp Surgical.
• Interest expense decreased by 16% for the three months and 15% for the six months, primarily due to lower interest rates and average debt balances.
• Net cash provided by operating activities increased by 22.7% for the six months, reflecting strong cash generation from core operations.
• Cash used in investing activities decreased significantly for the six months, primarily due to lower acquisition payments compared to the prior year.

Negatives

• Net income for the three months ended April 30, 2025, slightly decreased by 1.3% despite revenue growth, primarily due to a higher effective tax rate and a $15.7 million loss on the disposal of a minority interest investment.
• The effective tax rate increased significantly to 39.3% for the three months and 35.5% for the six months, impacting net earnings.
• Corporate operating loss increased by 26% for the three months and 3% for the six months, mainly due to higher share-based compensation expenses.
• CooperSurgical's operating income decreased by 4% for the six months ended April 30, 2025, primarily due to an increase in amortization expense.
• The company's Board of Directors decided to end the declaration of a semi-annual dividend in December 2023, which may negatively impact income-focused investors.

Risks

• Adverse changes in global or regional general business, political, and economic conditions, including inflation, foreign exchange rate fluctuations, and supply chain disruptions.
• Impact of international conflicts on the global and local economy, financial markets, energy markets, and currency rates.
• Challenges of managing substantial and expanding international operations and complying with diverse legal and regulatory requirements.
• The actual imposition or threats of tariffs, customs duties, and other trade barriers.
• Increased interest expense due to rate increases on existing and future variable rate indebtedness.
• Changes in tax laws, examinations by tax authorities, and shifts in the geographic composition of income.
• Acquisition-related adverse effects, including failure to achieve anticipated benefits, integration delays, and difficulties in obtaining regulatory approvals.
• Compliance costs and potential liability related to U.S. and foreign privacy and security laws (e.g., HIPAA, CCPA, GDPR), including data security breaches.
• Major disruptions in manufacturing, accounting, financial reporting, research and development, or distribution facilities due to various causes, including cybersecurity incidents or third-party vendor failures.
• Market consolidation of large customers, leading to a higher concentration of business from fewer customers.
• Disruptions in supplies of raw materials, particularly components for silicone hydrogel lenses.
• New U.S. and foreign government laws and regulations affecting the healthcare, contact lens, medical device, or pharmaceutical industries (e.g., EU MDR/IVDR).
• Legal costs, insurance expenses, settlement costs, and the risk of adverse decisions related to product liability, patent infringement, or other litigation.
• Limitations on sales following product introductions due to poor market acceptance.
• New competitors, product innovations, or technologies, including advances by competitors and their expansion through acquisitions.
• Reduced sales, loss of customers, and reputational harm from product recalls and warning letters.
• Failure to receive, or delays in receiving, regulatory approvals or certifications for products.
• Failure of customers and end users to obtain adequate coverage and reimbursement from third-party payers for products and services.
• The requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets, and idle manufacturing facilities and equipment.
• Risks related to environmental laws and requirements applicable to facilities, products, or manufacturing processes, including evolving regulations regarding hazardous substances.
• Risks related to environmental, social, and corporate governance (ESG) issues, including regulatory and disclosure requirements, climate change, and sustainability.

Future Outlook

The Cooper Companies remains optimistic about the long-term prospects for the worldwide contact lens and general healthcare markets, and the resilience and growth prospects for its businesses and products. The company expects to expand disclosures related to its operating segments starting with its Annual Report on Form 10-K for the fiscal year ending October 31, 2025, following new accounting pronouncements. Management believes current cash, cash equivalents, future operating cash flow, and available credit will be sufficient to meet anticipated cash needs for at least the next 12 months.

Management Comments

• "We are optimistic about the long-term prospects for the worldwide contact lens and general health care markets, and the resilience of and growth prospects for our businesses and products."
• Management believes that there will be lower contact lens wearer dropout rates as technology improves and enhances the wearing experience through a combination of improved designs and materials and the growth of preferred modalities such as single-use and monthly wearing options.
• CooperVision is focused on greater worldwide market penetration using recently introduced products and continues to expand its presence in existing and emerging markets, including through acquisitions.
• Management believes the efforts taken to date and the planned remediation will improve the effectiveness of the internal control over financial reporting, but controls must operate effectively for a sufficient period and be tested to be considered remediated.

Industry Context

The Cooper Companies operates in the global contact lens market through CooperVision, focusing on silicone hydrogel products, including single-use and frequent replacement options, and is expanding into myopia management. In the women's health and fertility market, CooperSurgical offers a diversified portfolio of products and services, including medical devices, cryostorage, contraception, and specialized fertility solutions. The company's growth is driven by technological advancements, market shifts towards preferred modalities like single-use lenses, and strategic acquisitions to expand its product offerings and market presence in both segments. The industry faces ongoing challenges from global macroeconomic conditions, regulatory changes, and competitive pressures.

Corporate Governance

Legal Proceedings

• The Company is involved in various lawsuits, claims, and other legal matters that arise in the ordinary course of business, including matters involving products, intellectual property, supplier relationships, distributors, competitor relationships, and employees.
• Management does not believe that the ultimate resolution of these proceedings or claims could have a material adverse effect on its financial condition or results of operations.

Stakeholder Impact

• Shareholders: Experience flat diluted EPS for the quarter, but growth for the six months. The cessation of semi-annual dividends may negatively impact income-focused shareholders. Share repurchases could provide some support to share price. The material weakness in internal controls introduces risk regarding financial reporting reliability.
• Employees: Increased share-based compensation expenses were noted. Remediation efforts for IT general controls include developing skill sets and additional training programs for employees.
• Customers: Benefit from continued product innovation, particularly in contact lenses (e.g., MiSight for myopia management) and expanded offerings in women's health and fertility through acquisitions.
• Creditors: The company remains in compliance with all debt covenants and has a new revolving credit facility, indicating stable creditworthiness.
• Suppliers: Disruptions in raw material supplies, particularly for silicone hydrogel lenses, remain a risk.

Next Steps

• Continue remediation efforts for the identified material weakness in IT general controls, including enhancing risk assessment, developing employee skill sets, and improving change management and user access controls.
• Make the second $50.0 million installment payment for the Cook Medical acquisition on November 1, 2025.
• Expand disclosures related to operating segments in the Annual Report on Form 10-K for the fiscal year ending October 31, 2025, and interim periods beginning November 1, 2025, due to new accounting pronouncements (ASU 2023-07).
• Evaluate the impact of new accounting pronouncements ASU 2024-03 (Expense Disaggregation Disclosures) and ASU 2023-09 (Improvements to Income Tax Disclosures) for future adoption.

Key Dates

Recommendation

Keywords

Contact Lenses, Women's Health, Fertility Solutions, Medical Devices, Myopia Management, Silicone Hydrogel, SEC Filing, Quarterly Report, Financial Results, Corporate Governance, Risk Management, The Cooper Companies